Skip to main content

Table 3 Number positive and frequency for AGE-IgG, rheumatoid factor, and anti-AGE-IgG antibodies in the patient groups at initial visit

From: Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis

 

Patient group

 

Serum finding

RF+ RA (n = 70)

RF- RA (n = 36)

SpA (n = 36)

UA (n = 89)

Normal (n = 20)

AGE-IgG+

14 (20%)

11 (31%)

9 (25%)

13 (15%)

1(5%)

IgM RF+ (by nephlometry)

70 (100%)*

0

2 (6%)

16 (18%)

NA

IgM RF+ (by ELISA)

64 (91%)* 1

6 (17%)2

6 (17%)

22 (25%)

1(5%)

Anti-AGE-IgG1+

27 (39%)*

5 (14%)

4 (11%)

15 (17%)

0

Anti-AGE-IgG3+

28 (40%)*

4 (11%)

4 (11%)

14 (16%)

0

  1. 1Fifty-four out of 66 (82%) were rheumatoid factor (RF) positive at the year 1 follow up; 22 out of 34 (6%) remained RF positive at the year 1 follow-up. *P < 0.05, between patient groups by analysis of variance or χ2 test, with Yates correction where appropriate. ELISA, enzyme-linked immunosorbent assay; NA, not available; RA, rheumatoid arthritis; SpA, spondyloarthropathy; UA, undifferentiated arthritis.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us